Nicolas J. Guzman, M.D. has been the Director of Nephrology Clinical Research at AstraZeneca since 2014. He previously served as Associate Professor of Medicine in the division of Renal Disease and Hypertension at the George Washington University Medical Center.
His areas of clinical expertise include chronic kidney disease, cardiovascular disease risk, acute renal failure and studying the relationship between renal disease and cardiovascular complications. Other areas of focus include arterial hypertension, specifically hypertension in chronic kidney disease, clinical pharmacology and toxicology, and medical education and technology. Dr. Guzman, an established research lead, has been invited to a variety of lectures and conferences to speak about his work. He has served on many scientific review, advisory and editorial review boards as a trusted expert. Dr. Guzman’s vast experience in the cardio-renal disease space continues to make him a valuable asset to AstraZeneca and to the chronic kidney disease franchise.
With chronic kidney disease affecting more than 200 million people worldwide, I am proud that AstraZeneca is taking the lead and is fully committed to building a portfolio that will establish us as a scientific leader in the cardio-renal space.
LATEST PROJECT
ASSOCIATE PROFESSOR
DIRECTOR OF ACUTE DIALYSIS AND RENAL SUPPORT SERVICES
DIRECTOR OF OUTPATIENT CLINICS
DIRECTOR OF DIABETES AND RENAL DISEASE CLINIC
DIRECTOR, MOLECULAR SIGNALING LABORATORY
Featured publications
Awards and honors
American Society of Hypertension
American Board of Internal Medicine
Diplomate
Our people share a common purpose: to push the boundaries of science to deliver life-changing medicines.
Stories from our people and our partners reveal the passion, energy and knowledge that enable us to put science at the heart of everything we do.
We are a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.
Join AstraZeneca
and help us deliver life-changing medicines
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.